In the latest analysis by Josh Brown and Sean Russo of Ritholtz Wealth Management, both Moderna (MRNA) and Delta Air Lines (DAL) are highlighted as stocks currently in pullbacks. Moderna has seen significant gains, rising 244% since being added to the Best Stocks list at $67.27, largely driven by advancements in personalized medicine and a promising cancer vaccine.
However, the stock has recently pulled back from a high of $281 to $223, with analysts suggesting a stop level at $202 to protect gains. Delta, which is up 29% since its initial recommendation at $67.10, has faced volatility due to fluctuating oil prices but reported strong Q3 earnings with record revenues.
Despite a recent rally, the stock's performance remains sensitive to fuel costs, and analysts recommend caution in the current setup. The FAA's recent grounding of flights did not significantly impact Delta's stock, indicating investor confidence. Overall, both stocks require careful monitoring of key price levels to manage potential risks